Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ZYBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -29.13% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 235.36M USD | Price to earnings Ratio 83.17 | 1Y Target Price - |
Price to earnings Ratio 83.17 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 3.50 - 14.30 | Updated Date 05/15/2025 |
52 Weeks Range 3.50 - 14.30 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.69% | Operating Margin (TTM) 15.71% |
Management Effectiveness
Return on Assets (TTM) 3.82% | Return on Equity (TTM) 7.15% |
Valuation
Trailing PE 83.17 | Forward PE - | Enterprise Value 246150989 | Price to Sales(TTM) 1.24 |
Enterprise Value 246150989 | Price to Sales(TTM) 1.24 | ||
Enterprise Value to Revenue 9.48 | Enterprise Value to EBITDA 31.36 | Shares Outstanding 47166400 | Shares Floating 4068874 |
Shares Outstanding 47166400 | Shares Floating 4068874 | ||
Percent Insiders 91.64 | Percent Institutions - |
Upturn AI SWOT
Zhengye Biotechnology Holding Limited Ordinary Shares
Company Overview
History and Background
Zhengye Biotechnology Holding Limited is a biotechnology company. Specific details regarding its founding year, significant milestones, and historical evolution are currently not readily available in public sources. Further research into the company's private filings or official documentation would be necessary to provide a complete historical overview.
Core Business Areas
- Biopharmaceutical Development: Focuses on the research and development of innovative biopharmaceutical products, addressing unmet medical needs in various therapeutic areas.
- Manufacturing and Production: Engages in the manufacturing and production of pharmaceutical products, potentially including both generic and branded medications.
- Distribution and Sales: Distributes and sells pharmaceutical products through various channels, potentially including hospitals, pharmacies, and other healthcare providers.
Leadership and Structure
Specific details regarding Zhengye Biotechnology Holding Limited's leadership team and organizational structure are currently not readily available in public sources. Further research into the company's official documentation or annual reports would be necessary to provide a detailed overview.
Top Products and Market Share
Key Offerings
- Product Name 1: Information on the specific products offered by Zhengye Biotechnology is not publicly available. Access to proprietary data would be needed to ascertain the company's key products, market share data, revenue contributions, and competitive landscape.
- Product Name 2: Information on the specific products offered by Zhengye Biotechnology is not publicly available. Access to proprietary data would be needed to ascertain the company's key products, market share data, revenue contributions, and competitive landscape.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by rapid innovation, high R&D costs, stringent regulatory requirements, and intense competition. It is driven by increasing healthcare demands, technological advancements, and an aging population.
Positioning
Without specific details on Zhengye Biotechnology's product portfolio and market share, it is difficult to accurately determine its positioning within the biotechnology industry. The company's competitive advantage would depend on factors such as innovative technologies, product efficacy, cost-effectiveness, and market access.
Total Addressable Market (TAM)
Due to the lack of information on Zhengye Biotechnology's specific activities, we are unable to define it's TAM. Therefore, we are unable to ascertain how it is positioned to capture this TAM.
Upturn SWOT Analysis
Strengths
- Potential for innovative biopharmaceutical products
- Manufacturing capabilities (if established)
- Distribution network (if established)
Weaknesses
- Limited publicly available information
- Dependence on R&D success
- Exposure to regulatory risks
Opportunities
- Expanding into new therapeutic areas
- Partnering with established pharmaceutical companies
- Capitalizing on growing demand for biotechnology products
Threats
- Intense competition from established players
- Patent expirations
- Adverse regulatory changes
Competitors and Market Share
Key Competitors
Competitive Landscape
Due to lack of available financial information, this section can not be completed
Growth Trajectory and Initiatives
Historical Growth: Due to lack of available financial information, this section can not be completed
Future Projections: Due to lack of available financial information, this section can not be completed
Recent Initiatives: Due to lack of available financial information, this section can not be completed
Summary
Zhengye Biotechnology Holding Limited's profile is limited by the scarcity of publicly available information. Evaluating their strength and future outlook requires deeper access to internal data on products, finances, and strategic initiatives. Due to the lack of available data, it is difficult to provide an assessment of the company's current standing and prospective growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available company information
- Industry reports
Disclaimers:
The information provided is based on limited publicly available data and should not be considered financial advice. Investors should conduct their own thorough research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zhengye Biotechnology Holding Limited Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2025-01-07 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 278 | Website https://www.jlzybio.com |
Full time employees 278 | Website https://www.jlzybio.com | ||
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.